Atopic Dermatitis, Phase 2a
KY1005 is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. KY1005 is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. We believe this mechanism-of-action means KY1005 could be applicable to a range of autoimmune and inflammatory diseases. In our Phase 1 clinical trial in healthy volunteers, KY1005 was able to block T cell-driven skin inflammation while being well tolerated. We are conducting a Phase 2a clinical trial for the treatment of Atopic Dermatitis and expect preliminary results in 2020. We believe the immune-modulating mechanism of KY1005 has broad potential therapeutic application in multiple diseases caused by immune dysregulation.
Kymab's Expanded Access Policy for KY1005 (PDF document)